Pages that link to "Q33850032"
Jump to navigation
Jump to search
The following pages link to Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses (Q33850032):
Displayed 50 items.
- Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies (Q24599295) (← links)
- DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice (Q24701765) (← links)
- Advanced vaccine candidates for Lassa fever (Q26823627) (← links)
- Mouse models for filovirus infections (Q27011569) (← links)
- Envelope exchange for the generation of live-attenuated arenavirus vaccines (Q27320211) (← links)
- A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins (Q27473027) (← links)
- Sindbis Virus Vectors Designed To Express a Foreign Protein as a Cleavable Component of the Viral Structural Polyprotein (Q27473478) (← links)
- A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques (Q27484994) (← links)
- Replicon RNA Viral Vectors as Vaccines (Q28076639) (← links)
- Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target (Q30227194) (← links)
- Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. (Q30382097) (← links)
- Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses (Q30429787) (← links)
- A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses (Q33226128) (← links)
- Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats (Q33351971) (← links)
- Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus (Q33617793) (← links)
- VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever (Q33723534) (← links)
- Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles (Q33920185) (← links)
- Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins (Q34123838) (← links)
- Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors (Q34291021) (← links)
- Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever (Q34322342) (← links)
- Mucosal and systemic adjuvant activity of alphavirus replicon particles. (Q34410789) (← links)
- A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge (Q34434713) (← links)
- Reverse genetics approaches to combat pathogenic arenaviruses (Q34596958) (← links)
- Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials (Q34671806) (← links)
- Alphavirus vectors and vaccination (Q34812016) (← links)
- Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man (Q35248863) (← links)
- Advances in virus-like particle vaccines for filoviruses (Q35300029) (← links)
- Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection (Q35300104) (← links)
- A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses (Q35463993) (← links)
- Filovirus vaccines. (Q35558539) (← links)
- A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model (Q35806060) (← links)
- Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs (Q35814851) (← links)
- Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. (Q35826698) (← links)
- Alphavirus replicon approach to promoterless analysis of IRES elements. (Q35828303) (← links)
- A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity (Q35842756) (← links)
- Successful topical respiratory tract immunization of primates against Ebola virus (Q35857218) (← links)
- Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues (Q35857273) (← links)
- Lassa virus (Q35919691) (← links)
- Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins (Q35946943) (← links)
- Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus (Q36037316) (← links)
- Filovirus-like particles as vaccines and discovery tools (Q36198685) (← links)
- Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats (Q36315159) (← links)
- Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers (Q36482804) (← links)
- Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model (Q36581311) (← links)
- The search for animal models for Lassa fever vaccine development (Q36588064) (← links)
- Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle. (Q36591679) (← links)
- Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers (Q36612929) (← links)
- Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics (Q36943931) (← links)
- Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates (Q36970552) (← links)
- Therapeutic and prophylactic applications of alphavirus vectors (Q37322650) (← links)